1. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis 
Mohamad B. Sonbol, Belal Firwana, Talal Hilal, Zhen Wang, Diana Almader-Douglas, Richard W. Joseph, Thai H. Ho 
European Urology Oncology 
Volume 1, Issue 2, Pages (June 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Meta-analysis of antiangiogenics versus placebo for the overall cohort. VEGFi=VEGF inhibitor.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

3. Fig. 2
Meta-analysis of sunitinib versus placebo for the overall cohort. VEGFi=VEGF inhibitor.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

4. Fig. 3
Meta-analysis of (A) antiangiogenics versus placebo and (B) sunitinib versus placebo for any grade ≥3 AEs, discontinuations due to AEs, and grade 5 AEs (death). AE=adverse event; VEGFi=VEGF inhibitor.
European Urology Oncology 2018 1, DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions

5. European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018
Copyright © 2018 European Association of Urology Terms and Conditions

6. European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018
Copyright © 2018 European Association of Urology Terms and Conditions

7. European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018
Copyright © 2018 European Association of Urology Terms and Conditions

8. European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018
Copyright © 2018 European Association of Urology Terms and Conditions

9. European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018
Copyright © 2018 European Association of Urology Terms and Conditions

10. European Urology Oncology 2018 1, 101-108DOI: (10. 1016/j. euo. 2018
Copyright © 2018 European Association of Urology Terms and Conditions